Garb Oil and Power Corp (GARB): Hmm… seems that way $GARB

Play Episode

3min

Proactive - Interviews for investors

Quantum Base to list on AIM with £5M IPO plan

Quantum Base CEO Tom Taylor joined Stephen Gunnion in the Proactive studio with more about the company’s upcoming listing on the AIM market and its breakthrough anti-counterfeiting technology. Quantum Base, founded in 2013 as a spin-out from Lancaster University, has developed an atomic fingerprint that offers 100% secure authentication of goods, scannable with any smartphone. “It tells you 100% if something is real or it's fake,” Taylor said, describing the technology as a major leap in the fight against counterfeiting. Taylor explained that the technology has applications across sectors including brand protection, pharmaceuticals, tax stamps, banknotes, passports and even aerospace parts. The firm is already working with clients globally—from North America to the Middle East—and targeting both commercial brands and government organisations. The IPO is expected to raise £5 million, with £4.70 million already committed and trading set to begin on Friday under the ticker QUBE. The retail offer remains open. “We really want to grow… AIM really helps us grow,” Taylor said, noting the listing will support product development and expansion into new verticals. Key uses of the funds will include expanding Quantum Base’s commercial team and scaling its product reach into global markets. Looking ahead, Taylor said investors should watch for announcements of new customers and entry into new industries as milestones on the path to profitability. For more interviews like this, visit Proactive's YouTube channel. Don’t forget to give this video a like, subscribe to the channel, and enable notifications to stay updated. #QuantumBase #TomTaylor #AntiCounterfeiting #AtomicFingerprint #AIMListing #IPO2025 #SmartphoneSecurity #PharmaceuticalSecurity #BrandProtection #QuantumTech #QUBE #InvestmentNews #ProactiveInvestors

Proactive - Interviews for investors

Tonix Pharmaceuticals launches :TONIX ONE™ A digital breakthrough in migraine management

Tonix Pharmaceuticals is making waves in the healthcare industry with the launch of TONIX ONE™ a fully integrated digital platform designed to empower migraine patients with better tools for understanding and managing their condition. In an exclusive discussion with Proactive’s Steve Darling, Dr. Seth Lederman, CEO of Tonix Pharmaceuticals, unveiled the platform’s innovative features and strategic partnerships aimed at transforming migraine care. By collaborating with UpScript Telemedicine, ProModRx, Blink Health, and a leading mobile application specializing in disease tracking, symptom reporting, and management, TONIX ONE offers a comprehensive, patient-centric solution. Dr. Lederman highlighted that TONIX ONE™ beyond conventional migraine education by providing critical insights into the limitations of oral medications, which can sometimes result in delayed or ineffective symptom relief. The platform bridges the gap between patients and healthcare providers, offering direct access to migraine specialists via telehealth consultations and seamless e-prescription requests—ensuring a faster, more effective pathway to treatment. With this initiative, Tonix Pharmaceuticals aims to not only educate and empower patients in their treatment journey but also eliminate the barriers to care that many migraine sufferers face. By integrating advanced digital health solutions,TONIX ONE™ stands at the forefront of a new era in migraine management, offering patients greater control over their health and well-being. #proactiveinvestors #tonixpharmaceuticalsholdingcorp #nasdaq #tnxp #Biotech #MigraineTreatment #TonixOne #DigitalHealth #Telemedicine #ZembraceSymTouch #Tosymra #HealthcareInnovation #PharmaNews #ProactiveInvestors

Proactive - Interviews for investors

OKYO Pharma achieves key stability milestone for Urcosimod in clinical development

OKYO Pharma CEO Gary Jacob joined Steve Darling from Proactive to share a significant advancement in the company’s ongoing drug development efforts. The company has successfully demonstrated that urcosimod—formerly known as OK-101—remains stable for more than two and a half years in single-use ampoules, which are used for patient administration. This milestone is a crucial step forward in ensuring the long-term viability of the drug as it progresses through clinical trials. Urcosimod is currently being evaluated in a Phase 2b clinical trial, which is a randomized, placebo-controlled, double-masked study involving 48 patients. The trial is focused on assessing the drug’s effectiveness in treating neurotrophic keratopathy (NCP), a serious and progressive degenerative eye disease. Jacob emphasized that achieving success in clinical development extends beyond obtaining positive clinical trial data. A crucial aspect of regulatory approval includes meeting the rigorous Chemistry, Manufacturing, and Controls (CMC) requirements set by the U.S. Food and Drug Administration (FDA). By demonstrating long-term stability, OKYO Pharma has strengthened its regulatory submission package, addressing an essential factor in the drug’s future approval and commercialization. The company recently completed Good Manufacturing Practice (GMP) stability assay testing of single-use ampoules containing urcosimod in an ophthalmic solution. The results were highly promising—ampoules stored under refrigerated conditions maintained stability for over two and a half years, while initial three-month data from samples stored at room temperature showed potency levels at or above 100%. These findings reinforce confidence in urcosimod’s shelf life and its potential for real-world clinical use. As OKYO Pharma continues to advance urcosimod through the regulatory and clinical development process, this stability milestone represents a critical achievement in its journey toward providing an effective tr

Proactive - Interviews for investors

European defense spending boom: Key investment opportunities amid global shifts

Jane Edmondson, Head of Index Product Strategy at TMXVettaFi, joined Steve Darling from Proactive to discuss the rapidly evolving global defense landscape and its investment implications. With geopolitical tensions on the rise and shifting defense priorities, investors must navigate new opportunities and risks in the sector. Edmondson highlighted Europe's unprecedented surge in defense spending, a direct response to the U.S. decision to scale back military aid to Ukraine. Central to this shift is the European Union’s €800 billion "Rearm Europe Readiness 2030" initiative, aimed at bolstering military preparedness. This includes substantial investments across key defense technologies and a dedicated €150 billion credit facility to enhance military capabilities. “There’s going to be a lot of spending to come,” Edmondson noted, emphasizing major growth areas such as artificial intelligence, cyber defense, drone technology, and advanced artillery systems. She pointed out that leading European defense firms—including Rheinmetall, BAE Systems, Thales, Dassault, and Leonardo SPA—stand to benefit significantly from this expansion. Additionally, South Korea’s Hanwha Aerospace is emerging as a key player in global defense contracts. In contrast, U.S. defense companies are experiencing headwinds due to budget cuts and canceled procurement deals, leading to a relative downturn in the sector. Another critical shift in global defense procurement is unfolding as traditional U.S. allies reconsider their defense purchases. Canada and Portugal, for instance, are re-evaluating orders for U.S.-made F-35 fighter jets in favor of alternative options, such as aircraft from Dassault Aviation. Edmondson stressed that these geopolitical realignments are creating strong economic tailwinds, particularly for Germany, which is set to invest an estimated €500 billion in defense over the next several years. She cited a recent Goldman Sachs report, which projects that half of this spending will

Followers	24
Posts	3926
Boards Moderated	1
Alias Born	05/28/2020

Volume:	-
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

GARB Detailed Quote

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Go Ad-Free